Clinical trials: Stable Coronary Artery Disease CAD
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in patients with stable coronary heart disease…
- Trial name
- NCT01516541
- Testing
- Background care, dalcetrapib
- Where
- 241 sites in United States, Australia and 11 more
- Volunteers
- 2,220 people
- Sponsor
- Hoffmann-La Roche
Stable Angina, Unstable Angina
Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS
The purpose of the study is to demonstrate the non-inferiority of Cre8 (CID) Drug Eluting Stent, studied 3 months after implant, compared to Vision/Multilink8 Bare Metal Stent (Abbott) studied at 1 month, in terms of neointimal…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEMONSTRATE (NCT01543373)
- Testing
- Amphilimus Eluting Stent, Bare Metal Stent
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 38 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Heart Disease
SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)
The overall objective of this integrated analysis is to evaluate the clinical safety and efficacy of long-term treatment with darapladib enteric coated tablets, 160mg, as compared to placebo when added to standard of care in…
- Trial name
- NCT01636271
- Testing
- darapladib
- Volunteers
- 28,855 people
- Sponsor
- GlaxoSmithKline
Angina Pectoris, Coronary Heart Disease
A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
This study will assess the safety of telcagepant in coronary artery disease (CAD) participants with stable angina during exercise treadmill testing and evaluate whether calcitonin gene-related peptide (CGRP) receptor antagonism…
- Conditions
- Angina Pectoris, Coronary Heart Disease, Calcitonin Gene-related Peptide Receptor
- Trial name
- NCT01294709
- Testing
- telcagepant
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
Stable Coronary Heart Disease (CHD)
Ticagrelor China Pharmacokinetic/Pharmacodynamic Study
open label, single centre, randomised, Phase IV, pharmacokinetic, pharmacodynamic, and safety study to evaluate single and multiple doses of 45, 60, and 90 mg of ticagrelor in Chinese patients with stable coronary heart disease
- Trial name
- NCT02064985
- Testing
- Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)
- Where
- China
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease
This study is designed to find out how safe nitroglycerin is and how it affects the body when it is taken together with another medicine called nurandociguat in people who have coronary artery disease (CAD).
- Trial name
- NCT07431294
- Testing
- Nitroglycerin spray, Nurandociguat
- Where
- 5 sites in Bulgaria, Germany
- Volunteers
- 36 people
- Sponsor
- Bayer
Coronary Artery Disease, Stable Angina Pectoris
A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT
The objective of this study is a comparative evaluation of BuMA Supreme™ stent and of Xience V/Prime stent in terms of the extent of neointima formation at 1 or 2 months after implanting in relatively high bleeding risk patients…
- Conditions
- Coronary Artery Disease, Stable Angina Pectoris, Unstable Angina Pectoris
- Trial name
- NCT02747329
- Testing
- BuMA Supreme™ stent, Xience V/Prime stent
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Stable Coronary Artery Disease
RBD1119 in Coronary Artery Disease (CAD)
CAD is driven by atherosclerosis in the coronary arteries and is a major cause of myocardial infarction, heart failure, arrhythmias, and premature death.
- Trial name
- NCT07884136
- Testing
- RBD1119
- Where
- 16 sites in Poland, Sweden
- Volunteers
- 200 people
- Sponsor
- Ribocure Pharmaceuticals AB
Coronary Artery Disease
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
METHOD is a prospective observational program that will be conducted in 1centre of the Russian Federation. Prospective follow-up will be for about 6 months.
- Trial name
- METHOD (NCT05210465)
- Testing
- speckle tracking mode of the stress ECHO test with dobutamine
- Where
- 2 sites in Russia
- Volunteers
- 36 people
- Sponsor
- Servier Russia
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.
Coronary Heart Disease, Stable Angina Pectoris
BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)
The objective of this study is a comparative evaluation of BuMA stent and of EXCEL stent in terms of the extent of neointima formation at 3 months after implantation using OCT.
- Conditions
- Coronary Heart Disease, Stable Angina Pectoris, Unstable Angina Pectoris, Silent Myocardial Ischemia
- Trial name
- NCT01752582
- Testing
- BuMA stent, EXCEL stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Diabetes Mellitus Type 2
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no…
- Trial name
- NCT01680978
- Testing
- aleglitazar
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Myocardial Ischemia
Gene Therapy for the Treatment of Chronic Stable Angina
The purpose of this study is to evaluate the safety and tolerability of catheter based injections of VM202 into the heart.
- Trial name
- NCT01002495
- Testing
- VM202
- Where
- 2 sites in United States
- Sponsor
- Helixmith Co., Ltd.
Coronary Artery Disease
PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
The study will be conducted at up to 25 U.S. centers and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD).
- Trial name
- PLASMA 2 (NCT00525954)
- Testing
- A-002
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- Anthera Pharmaceuticals
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV) injection, and to evaluate efficacy on the basis of the changes seen in the cardiac biomarkers and continuous electrocardiography (ECG)…
- Trial name
- SUPPORT-1 (NCT00984802)
- Testing
- CMX-2043
- Where
- 5 sites in United States, India
- Volunteers
- 142 people
- Sponsor
- Ischemix, LLC
Stable Coronary Artery Disease
A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- RESPOND (NCT00642811)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Stable Angina
Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention
Pressure intermittent coronary sinus occlusion (PICSO) in patients with coronary artery disease improves collateral flow index to higher than 30%. PICSO used in this patient population is safe, feasible and effective.
- Trial name
- PICSO (NCT01308125)
- Testing
- PICSO
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Miracor Medical SA
Angina, Stable
Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease
The purpose of this study is to determine whether a single intracoronary infusion of Ad5FGF-4, delivered during induced transient ischemia, is effective in improving myocardial perfusion, angina functional class, patient…
- Trial name
- ASPIRE (NCT01550614)
- Testing
- Alferminogene tadenovec
- Where
- Russia
- Volunteers
- 11 people
- Sponsor
- Cardium Therapeutics